Table 3. Multivariate Cox proportional hazard analysis of clinicopathological variables and MR imaging kinetic parameters with survival outcomes.
| Variable | Disease-free survival | ||
|---|---|---|---|
| P value | Hazard ratio | 95% CI | |
| Peak enhancement | 0.013 | 1.004 | 1.001, 1.006 |
| T stage | |||
| 1 | Reference | ||
| 2 | 0.220 | 1.669 | 0.737, 3.779 |
| 3 | 0.215 | 3.046 | 0.524, 17.698 |
| 4 | 0.998 | 0.000 | 0.000, ∞ |
| N stage | |||
| 0 | Reference | ||
| 1 | 0.591 | 1.267 | 0.534, 3.004 |
| 2 | 0.836 | 0.851 | 0.185, 3.914 |
| 3 | 0.081 | 3.040 | 0.872, 10.598 |
| Histologic grade | |||
| 1 | Reference | ||
| 2 | 0.131 | 3.227 | 0.704, 14.784 |
| 3 | 0.176 | 3.162 | 0.596, 16.775 |
| Molecular subtype | |||
| Luminal | Reference | ||
| HER2-enriched | 0.306 | 3.538 | 0.314, 39.828 |
| Triple-negative | 0.004 | 21.060 | 2.675, 165.780 |
| Adjuvant endocrine therapy | |||
| No | 0.263 | 3.282 | 0.409, 26.305 |
| Yes | Reference | ||
CI = confidence interval, HER2 = human epidermal growth factor receptor 2